Preventing and Treating Recurrent Hepatitis B After Liver Transplantation
Author Information
Author(s): Ian R. Schreibman, Eugene R. Schiff
Primary Institution: University of Miami Leonard M. Miller School of Medicine
Hypothesis
Can nucleoside and nucleotide analogues effectively prevent and treat recurrent Hepatitis B after liver transplantation?
Conclusion
Combination antiviral therapy can effectively prevent and treat recurrent Hepatitis B in liver transplant patients.
Supporting Evidence
- The use of Hepatitis B immunoglobulin (HBIG) has improved patient and graft survival rates.
- The addition of Lamivudine to HBIG has further improved survival rates.
- Combination therapy can minimize the risk of drug resistance.
Takeaway
Doctors can use special medicines to help people who had a liver transplant not get sick again from Hepatitis B.
Methodology
This review summarizes the efficacy of various antiviral regimens used to prevent and treat recurrent Hepatitis B following liver transplantation.
Potential Biases
Potential publication bias in the studies reviewed.
Limitations
The review is based on existing studies, which may have varying methodologies and sample sizes.
Participant Demographics
Patients undergoing liver transplantation for Hepatitis B-related liver disease.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website